ArticleBMC cancer2026
The Ki-67 proliferation index in tertiary lymphoid structures as a predictor of survival outcomes in patients with resectable non-small cell lung cancer.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
BACKGROUND &
objectivesAlthough the presence of tertiary lymphoid structures (TLS) has been associated with improved immunotherapy efficacy across multiple solid tumors, the prognostic significance of proliferative activity within TLS in patients with resectable non-small cell lung cancer (NSCLC) remains unclear. This study aims to evaluate the predictive value of Ki-67 expression within TLS for survival outcomes in patients with NSCLC and to explore the association between TLS maturity and the cellular proliferation index within these structures.
methodsPostoperative paraffin-embedded pathological specimens from 88 patients with NSCLC were analyzed. Hematoxylin-eosin (H&E) staining and immunohistochemistry (IHC) were performed to evaluate the presence, spatial distribution, and number of TLS. Multiplex immunofluorescence (mIF) staining was used to assess TLS maturity. Kaplan-Meier survival analysis was conducted to determine the prognostic significance of TLS maturity and the cellular proliferation index within TLS.
resultsTumor-associated TLS were identified in the tumor microenvironment of 74 (84.1%) of the 88 patients. The mature TLS was significantly associated with improved recurrence-free survival (RFS) in patients with NSCLC (P = 0.0068). The cellular proliferation index within TLS demonstrated a significant positive correlation with TLS maturity. Compared with early-stage TLS and primary follicular-like TLS, secondary follicular-like TLS exhibited a significantly higher proliferation index (P < 0.0001). Furthermore, a high TLS cellular proliferation index was predictive of favorable RFS in patients with NSCLC (P = 0.0231). Multivariate analysis further indicated that a high TLS cellular proliferation index was an independent favorable prognostic factor for RFS (HR = 0.487, 95% CI: 0.269-0.879; P = 0.017).
conclusionThis study demonstrates the prognostic relevance of the cellular proliferation index within TLS in the tumor microenvironment of NSCLC. A high TLS cellular proliferation index was significantly associated with prolonged RFS. These findings suggest that an elevated TLS cellular proliferation index may contribute to improved clinical outcomes by promoting TLS maturation and enhancing antitumor immune responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.